There's little to no time to waste this morning as the opening bell just rang.

StockWireNews

Former Nasdaq Biotech Champ (JAN) Is A Previous Approximate 400%+ Mover, Requires Immediate Attention

Yahoo Finance Reports Low Float (Approx. 2.38Mn Shares)

June 21st

Good Morning,

There's little to no time to waste this morning as the opening bell just rang.

Previously, I brought this past champ to your attention back on August 20th, 2020 and watched it rocket approximately $1.50+ on the day I alerted it.

Then, that's when things got interesting.

Fast-forward for a second to the beginning of January, 2021.On 1/28/21, this profile surged all the way to a 52-week high of $31.83.

From my initial alert back in August, this Nasdaq biotech had climbed over $25 and had delivered a run of approximately 448%.

Un-freaking-real.

Now, due to several potential catalysts, this past champ could be gearing up for another potential vertical surge.

For June 21st, there is only one profile to have on your radar:

JanOne Inc. (NASDAQ:JAN)

JanOne (Nasdaq: JAN) is focused on developing treatments for diseases that cause severe pain. By alleviating pain at the source, JanOne aims to reduce the need for op-ioid prescriptions to treat disease associated pain that can lead to op-ioid abuse. The company is also exploring solutions for non-addictive pain medications.

Its lead candidate, JAN101, is for potentially treating peripheral artery disease ("PAD"). JAN101 demonstrated positive results in a Phase 2a clinical trial, and Phase 2b trials are expected to begin in the near future. JanOne is dedicated to funding resources toward innovation, technology, and education for PAD, associated vascular conditions, and neuropathic pain.

Peripheral Artery Disease (PAD) - What You Need To Know

Peripheral Artery Disease (PAD) impacts about 12 million people in the U.S. alone. If left untreated, it could also lead to a Critical Limb Ischemia: a severe condition with an annual cost of care estimated to be $10Bn. 1 in every 20 adults over age 50, and 1 in every 4 adults over age 70, are also likely to develop PAD.(2)

So far, results from JanOne’s Phase 2a clinical trials support the use of sodium nitrite for the treatment and prevention of Peripheral Artery Disease.(3)

Nearing Phase 2b trials, JanOne could help address this painful ailment in a potential $5.7Bn PAD market.(1)

And, recent positive Phase 2b trial news could draw serious attention to JAN. Check it out:

Your No. 1 Potential JAN Catalyst

JanOne Advances Toward Initiation of Phase 2b Peripheral Artery Disease (PAD) Trial for Lead Product Candidate JAN101

Successfully Completes Initial Batch Production of JAN101, Demonstrating CGMP-scale Production Capabilities

LAS VEGAS, June 8, 2021 /PRNewswire/ -- JanOne Inc. (Nasdaq: JAN), a company focused on developing treatments for conditions that cause severe pain and dr-ugs with non-addictive, pain-relieving properties, today announced the successful completion of Current Good Manufacturing Practices (CGMP) production of the first batch of JAN101 for its upcoming Phase 2b trial for treating Peripheral Artery Disease (PAD).

[...]

Read the full article here.

-----

Your No. 2 Potential JAN Catalyst

Yahoo Finance is reporting that JAN has a minuscule 2.38Mn shares in its float.

2.38Mn... That's all!

Why is that important? When a st-ock's share structure is such, volatility can potentially take place in the flash of an eye.

With a biotech company, good trial/product news can be a true game-changer and bring serious attention to its st-ock.

-----

Your No. 3 Potential JAN Catalyst

According to Barchart, JAN is currently a "72% BUY" based on overall technical indicators.

Further, Barchart reports that JAN was a "24% SELL" last month. That's a big swing in a short amount of time.

Here are the bullish, triggered technicals the website is reporting (as of close Friday):

Short Term Indicators

  • 20 Day Moving Average
  • 20 - 50 Day MACD Oscillator
  • 20 - 200 Day MACD Oscillator

Medium Term Indicators

  • 50 Day Moving Average
  • 50 - 150 Day MACD Oscillator
  • 50 - 200 Day MACD Oscillator

Long Term Indicators

  • 100 Day Moving Average
  • 150 Day Moving Average
  • 200 Day Moving Average
  • 100 - 200 Day MACD Oscillator

Additionally, Barchart's composite "TrendSpotter" technical indicator is triggered as bullish.

-----

Your No. 4 Potential JAN Catalyst

Take a look at JAN's 6-month chart:

image

Right now, JAN is trading from strong potential support and above these key lines:

  • 5-Day Exponential Moving Average (EMA)
  • 13-Day Exponential Moving Average
  • 50-Day Simple Moving Average (SMA)
  • 200-Day Simple Moving Average

Why is this important? When a profile trades above these 4 lines, people may gain confidence from these levels holding as potential support for a vertical surge.

Plus, JAN's 5-Day EMA is trading above its 13-Day EMA which signals a profile trending in the right direction.

Could JAN be poised for another potential $25+ breakout like we saw over the past year and in the chart above?

Now, I'm not saying that JAN will go surging to that 52-week high today, but between its chart history and low float, you need to be aware of its breakout upside potential.

-----

Your No. 5 Potential JAN Catalyst

JanOne Appoints Internationally Renowned Expert on Addiction Nicholas Goeders, Ph.D. to Scientific Advisory Board

World leader in addiction science joins team of experts in diseases and disorders that cause chronic pain

LAS VEGAS, June 15, 2021 /PRNewswire/ -- JanOne Inc. (Nasdaq: JAN), a company focused on developing treatments for conditions that cause severe pain and dr-ugs with non-addictive, pain-relieving properties, today announced the appointment of Nicholas E. Goeders, Ph.D. to its Scientific Advisory Board (SAB). Dr. Goeders is considered one of the world's leaders on the role of stress in dr-ug addiction.

Tony Isaac, President and Chief Executive Officer of JanOne, commented, "JanOne's mission is to develop non-addictive medications to treat diseases that cause severe pain, thereby mitigating the use and abuse of harmful op-ioid pa-inkill-ers. With his world-class reputation as a foremost expert in addiction science, Dr. Goeders is ideally suited to join our advisory team of scientific and medical experts in vascular pathophysiology, including peripheral artery disease (PAD), and pain management across a broad range of chronic diseases and disorders. We are excited to welcome Dr. Goeders to our SAB at this important stage in our Company's history as we advance our treatment for PAD into Phase 2b clinical trials."

Tony Giordano, Ph.D., Chief Scientific Officer of JanOne, added, "Dr. Goeders' dedication to the field of addition has produced research and findings that are virtually unmatched in scope and consequence. He will be an outstanding addition to our esteemed Scientific Advisory Board."

Dr. Goeders is professor and head of the Department of Pharmacology, Toxicology and Neuroscience at Louisiana State University (LSU) Health Sciences Center Shreveport, where he has been a member of the faculty since 1985. He is also a co-founder of Embera NeuroTherapeutics, Inc., developer of a novel pharmacotherapy treatment for substance use disorders that is based on results from his research on stress and addiction. Prior to 1985, Dr. Goeders was a Staff Fellow of the National Institute on Dr-ug Abuse (NIDA) at the Addiction Research Center in Baltimore, Maryland and a Postdoctoral Fellow at The Johns Hopkins University School of Medicine, Department of Neuroscience. He received his Doctor of Philosophy from the Louisiana State University Medical Center with a major in Pharmacology. Dr. Goeders holds seven patents based on his research which has been actively funded by the National Institutes of Health (NIH) since 1983. He has published 115 scientific papers in peer-reviewed journals and has presented the results of his research worldwide. He is a member of the American College of Neuropsychopharmacology, a former member of the Board of Directors and a current Fellow of the College on Problems of Dr-ug Dependence, the Neuropharmacology Division of the American Society for Pharmacology and Experimental Therapeutics, the Behavioral Pharmacology Society, and the Society for Neuroscience.

"I am delighted to be able to contribute my knowledge to the very important work JanOne is doing to reduce risk associated with op-ioid addiction and overdose," said Dr. Goeders. "PAD associated pain can be severe, and nearly 25% of all those with PAD are at risk for addiction when being prescribed op-ioids to treat chronic neuropathic pain. I look forward to working with the talented team at JanOne and alongside the distinguished members of its SAB on the Company's fight against op-ioid addiction."

Read the full article here.

-----

Recap - Top JAN Potential Catalysts To Know

1. Important Phase 2b Trial News

2. Low Float

3. Bullish Technicals

4. Trading From Strong Potential Support

5. A Recent Game-Changing Hire

-----

Coverage is officially initiated on JAN. When you have time, do this later:

image

If there are any updates today, I'll get them out to you quickly.

Sincerely,

Kai Parker

StockWireNews


Source 1
Source 2
Source 3


(Always Remember The Stock Prices Could Be Significantly Lower Now From The Dates I Provided.)

Disclosure: I am not a lice.nsed finan.cial adviser. All potential percentage gains are based on from the low to the high of day. StockWireNews full disclosure is to be read and fully understood before using StockWireNews website, or joining StockWireNews' email or text list. By viewing StockWireNews website and/or reading Stock Wire News email or text newsletter you are agreeing to StockWireNews full disclosure which can be read at www.stockwirenews.net/disclosure StockWireNews (stockwirenews . com) is owned by StockNewsWire LLC, a limited liability company. A member of Stock News Wire, LLC owns an interest in the limited liability company that owns and operates small cap firm . com (“SCF”), an interest in the limited liability company that owns and operates fierce investor . com (“FI”), an interest in the limited liability company that owns and operates stockstreetwire . com (SSW), and an interest in the limited liability company that owns and operates nasdaq wire news . com (NWN) . From time to time, StockWireNews, SCF, FI, SSW, and/or NWN will publicly disseminate information about a company via website, email, SMS and other points of media. Pursuant to an agreement between StockNewsWire LLC and Venado Media, LLC, StockWireNews was hired for a period beginning on 8/20/20 and ending on 8/21/20 to publicly disseminate information about (JAN) via Website, Email and SMS. We were paid twenty-two thousand five hundred USD via bank wire transfer. We own zero shares of (JAN). Pursuant to an agreement between StockNewsWire LLC and Venado Media, LLC, StockWireNews was hired for a period beginning on 8/27/20 and ending on 8/28/20 to publicly disseminate information about (JAN) via Website, Email and SMS. We were paid seven thousand five hundred USD via bank wire transfer. We own zero shares of (JAN). Pursuant to an agreement between StockNewsWire LLC and Legends Media LLC, StockWireNews was hired for a period beginning on 6/21/21 and ending on 6/22/21 to publicly disseminate information about (JAN) via Website, Email and SMS. We were paid twenty-six thousand five hundred USD via bank wire transfer. We own zero shares of (JAN). To date, we have been compensated a total of fifty-six thousand five hundred USD via bank wire transfer to disseminate information about (JAN).